Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Companies / Glenmark’s new pain drug finishes phase-I trial
BackBack

Glenmark’s new pain drug finishes phase-I trial

Glenmark’s new pain drug finishes phase-I trial

Premium

Mumbai: Glenmark Pharmaceuticals Ltd on Monday said it has completed the phase-I trial of its new chronic pain drug candidate—GRC 15300, which has been out-licensed to French drug maker Sanofi SA for a total milestone valuation of $325 million (Rs 1,443 crore).

Glenmark in a statement said it is the first such pain drug entering clinical trials. It also said plans are in place to initiate clinical proof of concept studies in neuropathic pain indication.

GRC 15300, a potential next-generation treatment for various ailments, including diabetic neuropathic pain and osteoarthritic pain, was licensed by Sanofi for the rights of all therapeutic indications in May.

ch.unni@livemint.com

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 25 Jul 2011, 11:58 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App